Top Page
Catheter Precision
(NYSE MKT:VTAK)
Catheter Precision (VTAK) vs. SPDR S&P 500 ETF (SPY)
Catheter Precision Business Overview & Revenue Model
Catheter Precision Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 420.00K | 442.00K | 14.00K | 22.00K | 4.41M |
| Gross Profit | 378.00K | 412.00K | -147.00K | -1.54M | -1.08M |
| EBITDA | -11.30M | -15.11M | -22.37M | -27.70M | -33.30M |
| Net Income | -16.64M | -70.57M | -26.86M | -25.07M | -36.05M |
Balance Sheet | |||||
| Total Assets | 27.77M | 30.74M | 16.84M | 21.04M | 33.44M |
| Cash, Cash Equivalents and Short-Term Investments | 2.87M | 3.56M | 15.86M | 15.04M | 23.91M |
| Total Debt | 1.79M | 372.00K | 124.17K | 2.26M | 4.88M |
| Total Liabilities | 16.01M | 9.54M | 7.58M | 7.37M | 12.29M |
| Stockholders Equity | 11.76M | 21.19M | 9.26M | 13.67M | 21.15M |
Cash Flow | |||||
| Free Cash Flow | -9.34M | -20.70M | -22.59M | -27.89M | -28.37M |
| Operating Cash Flow | -9.27M | -20.62M | -22.57M | -27.63M | -28.30M |
| Investing Cash Flow | -67.00K | -61.00K | 21.00K | 3.80M | 15.93M |
| Financing Cash Flow | 8.65M | 8.39M | 23.36M | 14.96M | 21.69M |
Catheter Precision Technical Analysis
Catheter Precision Risk Analysis
Catheter Precision Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$17.40B | 5.81 | -7.44% | 3.53% | 11.55% | -28.15% | |
54 Neutral | $26.27M | ― | -450.47% | ― | 9.47% | 81.37% | |
54 Neutral | $6.03M | ― | -233.04% | ― | -100.00% | 78.91% | |
45 Neutral | $1.09M | ― | -440.77% | ― | -1.21% | 93.72% | |
42 Neutral | $6.67M | ― | -155.20% | ― | 9.90% | 94.56% | |
41 Neutral | $1.96M | ― | -136.26% | ― | 9.57% | 10.03% | |
37 Underperform | $5.82M | ― | -120.16% | ― | -7.74% | 93.25% |
Catheter Precision Corporate Events
On July 25, 2025, Catheter Precision held its Annual Meeting of Stockholders, where six proposals were considered and approved, including the election of a director and several stock issuance proposals. A significant decision was the approval of a reverse stock split at a ratio of 1-for-19, effective August 15, 2025, aimed at maintaining the company’s compliance with NYSE American’s listing requirements. This reverse stock split will reduce the number of outstanding shares from approximately 23.3 million to 1.2 million, ensuring the company’s continued listing on its current exchange without altering stockholders’ equity percentage.
Catheter Precision announced that its LockeT product sales for Q2 2025 are on track to be the highest to date, surpassing Q2 2024 sales by over $84,000. The company has secured a new distributor in Italy and is seeking additional distributors in Spain, Portugal, and the UK, aiming to expand its European footprint. Three U.S. hospitals are expected to issue significant purchase orders for LockeT by the end of 2025, indicating strong market interest. The CE Mark approval for LockeT facilitates its sales in Europe, and a live demonstration is scheduled in Italy to boost product awareness.
On June 5, 2025, Catheter Precision, Inc.’s Board of Directors approved a warrant issuance to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to the company’s pipe financing closed on May 12, 2025. This warrant allows the purchase of 257,143 shares at $0.5424 per share, pending stockholder approval at the annual meeting on July 25, 2025. The warrant will expire on June 6, 2030, and neither it nor the underlying shares have been registered under the Securities Act of 1933.
On June 2, 2025, Catheter Precision, Inc. announced the discontinuation of employment for their Chief Commercial Officer, Marie-Claude Jacques. Executive Chairman and CEO David Jenkins will temporarily assume the role until a new replacement is found, which may impact the company’s commercial operations and leadership dynamics.
Catheter Precision has announced a new offering of common stock that will result in dilution for new investors. As of March 31, 2025, the net tangible book value per share was $(1.71), and after adjustments, it is expected to be $(0.95) per share. This represents an immediate increase in value for existing shareholders but a substantial dilution for new investors purchasing at the assumed offering price of $0.30 per share. The company may also raise additional capital, which could lead to further dilution.
On May 19, 2025, Catheter Precision, Inc. entered into an At Market Offering Agreement with Ladenburg Thalmann & Co. Inc. to potentially sell up to $1.3 million of its common stock. The proceeds from any sales will be used to fund operations and working capital. Ladenburg will sell shares based on the company’s instructions, adhering to legal and exchange rules. The agreement can be terminated by either party with notice, and Ladenburg will receive a 3% commission on sales.
On May 12, 2025, Catheter Precision, Inc. entered into a Securities Purchase Agreement with three investors, selling 1.5 million shares of its Series B Convertible Preferred Stock and issuing an additional 1.5 million shares as consideration for existing senior secured Convertible Promissory Notes of QHSLab, Inc. The company has reserved up to 8,574,000 shares of common stock for conversion and issued Series L warrants for purchasing up to 4,285,716 shares of common stock. The conversion and exercise of these securities are subject to stockholder approval, which the company plans to seek at its Annual Meeting on July 25, 2025. The Series B Convertible Preferred Stock has a fixed conversion price of $0.35 per share, while the Series L warrants have a 5 ½ year term and are exercisable at $0.50 per share. The securities offering was conducted under an exemption from registration requirements, and the company intends to register the shares for resale by May 27, 2025.
In February 2025, Catheter Precision, Inc. formed a subsidiary, Cardionomix, Inc., to acquire assets from Cardionomic, Inc., which had ceased operations. On April 18, 2025, Cardionomix entered into an agreement to purchase assets related to a late-stage treatment for acute decompensated heart failure, including patents and trademarks for the Cardiac Pulmonary Nerve Simulation System. The acquisition was finalized on May 5, 2025, with Catheter Precision issuing 1,000,000 restricted shares and Cardionomix providing a $1.5 million promissory note. This strategic acquisition aims to enhance Catheter Precision’s portfolio in cardiac care, although it involves financial obligations and potential equity dilution for stakeholders.